Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.63 |
| ▸ | CTSG | P08311 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5969343 | 0.90 | ELANE (0.59) | ELANECTSGCMA1 | |
| SCHEMBL6678314 | 0.87 | ELANE (0.47) | ELANECTSGPOLBCMA1 | |
| SCHEMBL5969579 | 0.84 | ELANE (0.65) | ELANECTSGCMA1 | |
| SCHEMBL5969315 | 0.84 | ELANE (0.63) | ELANECTSGCMA1 | |
| SCHEMBL5969408 | 0.84 | ELANE (0.65) | ELANECTSGCMA1 | |
| SCHEMBL5969393 | 0.83 | ELANE (0.67) | ELANECTSGCMA1 | |
| SCHEMBL5969645 | 0.83 | ELANE (0.64) | ELANECTSGCMA1 | |
| SCHEMBL5969525 | 0.83 | ELANE (0.64) | ELANECTSGCMA1 | |
| SCHEMBL6276132 | 0.82 | ELANE (0.57) | ELANECTSGCMA1 | |
| SCHEMBL4463484 | 0.81 | ELANE (0.53) | ELANECTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067491-B2 | Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2006-06-27 | — | — | US | claimed |
| US-20050085424-A1 | Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-04-21 | — | — | US | claimed |
| EP-1473302-A1 | HETEROCYCLIC COMPOUNDS HAVING ELASTASE−INHIBITING ACTIVITY AND INTERMEDIATES THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 2004-11-03 | — | — | EP | claimed |
| US-7067491-B2 | Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20050085424-A1 | Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1473302-A1 | HETEROCYCLIC COMPOUNDS HAVING ELASTASE−INHIBITING ACTIVITY AND INTERMEDIATES THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085424-A1 | Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof | SERPINB1, ELANE, CELA1 | ELANE 2/4885CTSG 124/4885POLB 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.